References
- McLaughlin P, Grillo-Lopez A J, Link B K, Levy R, Czuczman M S, Williams M E, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–2833
- NCI. Common terminology criteria for adverse events, http://ctep.cancer.gov/forms/CTCAE
- Mabthera, summary of product characteristics, http://www.emea.eu.int/humandocs/PDFS/EPAR/Mabthera/025998en4.pdf. Accessed August 2004
- Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999; 94: 2217–2224
- Dillman R O. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev 1999; 18: 465–471
- Provencio M, Cerdeira S, Bonilla F, Sanchez A, Espana P. Rapid-infusion rituximab in lymphoma treatment. Ann Oncol 2006; 17: 1027–1028
- Salar A, Casao D, Cervera M, Pedro C, Calafell M, Abella E, et al. Rapid infusion of rituximab with or without steroid-containing chemotherapy: 1-year experience in a single institution. Eur J Haematol 2006; 77: 338–340
- Sehn L, Donaldson J, Filewich A, Fitzgerald C, Gill K K, Runzer N, et al. Rapid infusion rituximab in combination with steroid containing chemotherapy can be given safely and substantially reduces resource utilization. Blood 2004; 104, (abstract 1407)
- Middleton H, Mollee P, Bird R, Mills A K, Marlton P, Gill D. Accelerated delivery of rituximab is safe on an out-patient basis. Blood 2005; 106(Suppl.)
- Aurran-Schleinitz T, Gravis G, Vittot M, Coso D, Rey J, Schiano J M, et al. “One hour” rituximab infusion is safe and improves patient care and outpatient unit management. Blood 2005; 106(Suppl.)
- Ghielmini M, Negretti L, Lerch E, Roth B, Voegeli M, Terrot T, et al. Infusion speed-escalation trial to give full-dose rituximab in one hour without steroids pre-medication. Blood 2005; 106(Suppl.)
- Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242
- Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417–1423
- Byrd J, Peterson B L, Morrison V A, Park K, Jacobson R, Hoke E, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003; 101: 6–14
- Sehn L H, Donaldson J, Filewich A, Fitzgerald C, Gill K K, Runzer N, et al. Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting. Blood 2007; 109: 4171–4173